FI955215A0 - Hallitusti vapauttavat oksibutyniinivalmisteet - Google Patents

Hallitusti vapauttavat oksibutyniinivalmisteet

Info

Publication number
FI955215A0
FI955215A0 FI955215A FI955215A FI955215A0 FI 955215 A0 FI955215 A0 FI 955215A0 FI 955215 A FI955215 A FI 955215A FI 955215 A FI955215 A FI 955215A FI 955215 A0 FI955215 A0 FI 955215A0
Authority
FI
Finland
Prior art keywords
oxybutyn
controlled release
release formulations
sustained release
solid oral
Prior art date
Application number
FI955215A
Other languages
English (en)
Swedish (sv)
Other versions
FI955215A (fi
FI113337B (fi
Inventor
Anand R Baichwal
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22766272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI955215(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of FI955215A0 publication Critical patent/FI955215A0/fi
Publication of FI955215A publication Critical patent/FI955215A/fi
Application granted granted Critical
Publication of FI113337B publication Critical patent/FI113337B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI955215A 1994-03-04 1995-11-01 Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi FI113337B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/206,416 US5399359A (en) 1994-03-04 1994-03-04 Controlled release oxybutynin formulations
US20641694 1994-03-04
PCT/US1994/002926 WO1995023593A1 (en) 1994-03-04 1994-03-18 Controlled release oxybutynin formulations
US9402926 1994-03-18

Publications (3)

Publication Number Publication Date
FI955215A0 true FI955215A0 (fi) 1995-11-01
FI955215A FI955215A (fi) 1995-11-01
FI113337B FI113337B (fi) 2004-04-15

Family

ID=22766272

Family Applications (1)

Application Number Title Priority Date Filing Date
FI955215A FI113337B (fi) 1994-03-04 1995-11-01 Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi

Country Status (15)

Country Link
US (1) US5399359A (fi)
EP (1) EP0700284B1 (fi)
JP (2) JP3699117B2 (fi)
CN (1) CN1111404C (fi)
AT (1) ATE222753T1 (fi)
AU (1) AU676556B2 (fi)
CA (1) CA2161103C (fi)
DE (1) DE69431247T2 (fi)
DK (1) DK0700284T3 (fi)
ES (1) ES2180574T3 (fi)
FI (1) FI113337B (fi)
HU (1) HUT72981A (fi)
IL (1) IL112637A (fi)
PT (1) PT700284E (fi)
WO (1) WO1995023593A1 (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
ES2141044B1 (es) * 1997-02-26 2001-02-01 Alza Corp Terapia con oxibutinina.
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
EP1135106B1 (en) * 1999-09-30 2008-04-09 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
US7235258B1 (en) 1999-10-19 2007-06-26 Nps Pharmaceuticals, Inc. Sustained-release formulations for treating CNS-mediated disorders
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
MXPA03008293A (es) * 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CN1268338C (zh) * 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
HUP0402611A2 (hu) * 2001-10-08 2005-07-28 Sun Pharmaceutical Industries Limited Görcsoldó hatóanyag szakaszos leadására szolgáló rendszer
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
EP1549296A4 (en) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co METFORMIN FORMULATIONS WITH DELAYED RELEASE
JP4884772B2 (ja) * 2003-08-04 2012-02-29 杏林製薬株式会社 経口徐放性錠剤
WO2005027843A2 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
EP1680110B1 (en) * 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
RU2418672C2 (ru) 2005-03-15 2011-05-20 Хтк Свиден Аб Способ ухода, подходящий для ежедневного применения, за твердыми поверхностями пола из камня или камнеподобного материала
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
CA2636274C (en) 2006-01-05 2015-05-26 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
EA029077B1 (ru) * 2010-03-09 2018-02-28 Алкермес Фарма Айэленд Лимитед Устойчивая к спирту фармацевтическая лекарственная форма
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
CA3125835C (en) 2014-11-14 2023-01-03 Neil M. Cowen Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
DE102015014581A1 (de) * 2015-11-12 2017-05-18 Nele Schmidt Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS5630485A (en) * 1979-08-21 1981-03-27 Sansho Kk Heat insulation composition for heating and cooling
BE902605A (fr) * 1985-06-06 1985-09-30 Therabel Res S A N V Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
CA1272922A (en) * 1986-06-03 1990-08-21 Peter William Berry Drug delivery device, its preparation and use
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3714074A1 (de) * 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5207932A (en) * 1989-07-20 1993-05-04 Chubb National Foam, Inc. Alcohol resistant aqueous film forming firefighting foam
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
JPH04273818A (ja) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd 経皮投与製剤
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
DE69326848T2 (de) * 1992-05-13 2000-01-27 Alza Corp Oxybutynin zur transdermalen Verabreichung
JP2646170B2 (ja) * 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs

Also Published As

Publication number Publication date
DE69431247T2 (de) 2003-01-02
EP0700284A1 (en) 1996-03-13
PT700284E (pt) 2003-01-31
CA2161103A1 (en) 1995-09-08
HU9503054D0 (en) 1996-01-29
AU6588894A (en) 1995-09-18
CN1111404C (zh) 2003-06-18
DE69431247D1 (de) 2002-10-02
WO1995023593A1 (en) 1995-09-08
US5399359A (en) 1995-03-21
EP0700284A4 (en) 1996-11-06
IL112637A (en) 1999-01-26
FI955215A (fi) 1995-11-01
MX9501193A (es) 1998-07-31
AU676556B2 (en) 1997-03-13
JP3699117B2 (ja) 2005-09-28
CA2161103C (en) 1999-12-07
HUT72981A (en) 1996-06-28
JP2005126444A (ja) 2005-05-19
ES2180574T3 (es) 2003-02-16
DK0700284T3 (da) 2003-01-06
ATE222753T1 (de) 2002-09-15
IL112637A0 (en) 1995-05-26
FI113337B (fi) 2004-04-15
CN1111507A (zh) 1995-11-15
JPH09501445A (ja) 1997-02-10
EP0700284B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
DK0700284T3 (da) Oxybutyninformuleringer med kontrolleret frigivelse
ES2191034T3 (es) Formulaciones de liberacion controlada para la liberacion de metoprolol durante 24 horas.
AU550992B2 (en) Sustained release diethylpropion comppositions
CA2164619A1 (en) Once-a-day metoprolol oral dosage form
MX9704910A (es) Formula de liberacion controlada (albuterol).
GB9416600D0 (en) Pharmaceutical formulation
IT8024603A0 (it) Formulazioni a cessione controllata a base di fenbendazolo intimamente disperso attraverso una matrice copolimera.
GB9112495D0 (en) Improved formulations of acetazolamide